Pathways of chemotherapy resistance in castration-resistant prostate cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathways of chemotherapy resistance in castration-resistant prostate cancer
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 18, Issue 4, Pages R103-R123
Publisher
Bioscientifica
Online
2011-05-13
DOI
10.1530/erc-10-0343
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanism by Which Mcl-1 Regulates Cancer-Specific Apoptosis Triggered by mda-7/IL-24, an IL-10–Related Cytokine
- (2010) Rupesh Dash et al. CANCER RESEARCH
- Targeting prostate cancer based on signal transduction and cell cycle pathways
- (2010) John T. Lee et al. CELL CYCLE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells
- (2010) Shumin Zhang et al. Molecular Cancer
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Phase II study of sunitinib in men with advanced prostate cancer
- (2009) M. Dror Michaelson et al. ANNALS OF ONCOLOGY
- Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer
- (2009) Sowmyalakshmi Srinivasan et al. APOPTOSIS
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- 3,3'-Diindolylmethane Enhances Taxotere-Induced Apoptosis in Hormone-Refractory Prostate Cancer Cells through Survivin Down-regulation
- (2009) K. W. Rahman et al. CANCER RESEARCH
- Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
- (2009) L. Zhao et al. CANCER RESEARCH
- Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
- (2009) T. Satoh et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
- (2009) Kim N. Chi et al. EUROPEAN UROLOGY
- Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
- (2009) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
- (2009) William H. Allum et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer
- (2009) Emma Dean et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs
- (2009) Catherine Sánchez et al. PROSTATE
- Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer
- (2008) A. Hussain et al. ANNALS OF ONCOLOGY
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
- (2008) P Mathew et al. BRITISH JOURNAL OF CANCER
- C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer
- (2008) Tomasz M. Beer et al. CANCER
- The Role of Angiogenesis Inhibitors in Prostate Cancer
- (2008) Jeanny B. Aragon-Ching et al. CANCER JOURNAL
- Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
- (2008) Albana Cumashi et al. CANCER LETTERS
- Down-regulation of Mammalian Sterile 20-Like Kinase 1 by Heat Shock Protein 70 Mediates Cisplatin Resistance in Prostate Cancer Cells
- (2008) A. Ren et al. CANCER RESEARCH
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel
- (2008) T. M. Sissung et al. CLINICAL CANCER RESEARCH
- A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies
- (2008) S. S. Ramalingam et al. CLINICAL CANCER RESEARCH
- Heat Shock Protein 90 as a Drug Target: Some Like It Hot
- (2008) U. Banerji CLINICAL CANCER RESEARCH
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
- (2008) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells
- (2008) Marina Zemskova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
- (2008) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor- B Transcription and Evasion of Apoptosis
- (2008) C. Wilson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: The role of genes associated with the NF-κB pathway
- (2008) Irshad A.A. Shaikh et al. PROSTATE
- Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer
- (2008) Matteo Bellone et al. TRENDS IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search